<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321461</url>
  </required_header>
  <id_info>
    <org_study_id>TMTP1-ICG-02</org_study_id>
    <nct_id>NCT03321461</nct_id>
  </id_info>
  <brief_title>TMTP1-ICG Mapping in Colposcopy-directed Biopsy</brief_title>
  <official_title>Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Colposcopy-directed Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aimed to determine the validity of the novel tumor targeted fluorescent&#xD;
      TMTP1-ICG to increased accuracy of colposcopy-directed biopsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>1 day</time_frame>
    <description>Sensitivity of fluorescent detection of TMTP1-ICG compared to the sensitivity of ICG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>7 days</time_frame>
    <description>Specificity of fluorescent detection of TMTP1-ICG compared to the sensitivity of ICG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>TMTP1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMTP1</intervention_name>
    <description>Fluorescent sites will be removed</description>
    <arm_group_label>TMTP1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICG</intervention_name>
    <description>Fluorescent sites will be removed</description>
    <arm_group_label>ICG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspicious of cervical disease required a colposcopy-directed biopsy.&#xD;
&#xD;
          -  Subjects must sign an informed consent indicating awareness of the investigational&#xD;
             nature of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast-feeding or pregnant.&#xD;
&#xD;
          -  Ongoing participation in another clinical trial with an investigational drug with 3&#xD;
             months.&#xD;
&#xD;
          -  Own allergy towards ICG and/or alcohol.&#xD;
&#xD;
          -  Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases.&#xD;
&#xD;
          -  Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical Colledge, HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

